CHRO Chromocell Therapeutics Corporation Earnings per share for the last twelve months
The development of non-opioid analgesics is hindered by strict FDA control over molecular toxicity. The annual net income per share trend on this GURU.Markets platform chart shows that the value of -1.74 corresponds to the current metric. Chromocell Therapeutics (CHRO) maintains scientific authority in the study of sodium channels, which attracts physicians, while its ownership of patents for selective inhibitors ensures a steady stream of free cash flow.
Analytical breakdowns and data insights for company Chromocell Therapeutics Corp (CHRO)
- current quotes and average value forecast:
- market capitalization data:
- shareholders' equity book value data:
- debt and liquidity data:
Total Debt to Capital Chromocell Therapeutics|CHRO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Chromocell Therapeutics Corporation|CHRO - Company Debts|Debt to Book Capitalization Ratio Chromocell Therapeutics Corp.|CHRO - Company Long-Term Debt|Company Current Liabilities Chromocell Therapeutics|Quick Liquidity Indicator chromocell.com
- earnings and multiples data:
CHRO - Profit After Payment of Taxes|Projected Future Earnings Chromocell Therapeutics|CHRO - Company Value to Net Income|Forward P/E Multiple Chromocell Therapeutics Corp.|CHRO - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Chromocell Therapeutics Corp.|CHRO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Chromocell Therapeutics|CHRO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months chromocell.com|CHRO - Earnings per share trend in current year|Earnings growth forecast for next year Chromocell Therapeutics
- revenue and sales proceeds data:
Fundamental company valuation:CHRO - Chromocell Therapeutics
This metric is calculated by dividing the total annual net income by the total number of shares outstanding. The metric reflects the actual income per share, allowing for an assessment of business efficiency regardless of the issuance volume. For Chromocell Therapeutics (CHRO), this calculation demonstrates the financial return from the operation of the Chromovert platform and B2B contracts. By analyzing the fundamental net income per share TTM metric, an investor determines the long-term capitalization potential. This chart's dynamics reveal the resilience of the company's patent perimeter.
Competitor analysis for Chromocell Therapeutics
BIIB - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months neurocrine.com|Regencell Bioscience Holdings Limited (RGC) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Axsome|Earnings per share for the last twelve months ACADIA Pharmaceuticals Inc|Net earnings per one share for the last twelve months Xenon Corp XENE|Net earnings per share (EPS TTM) VKTX|Net earnings per share for the last 12 months supernus.com SUPN|Net earnings per share (EPS TTM) CPRX (Catalyst Pharmaceuticals, Inc.)|Denali (DNLI) - Net earnings per one share for the last twelve months|HRMY - Earnings per share for the last twelve months|BHVN: Earnings per share for the last twelve months|Amylyx Pharmaceuticals (AMLX) - Earnings per share for the last twelve months|TRVI (trevitherapeutics.com) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months PRAX|AVXL: Earnings per share for the trailing year|Net earnings per share for the last 12 months CBLL (CeriBell Corp)|Earnings per share for the last four quarters PRTA|Net earnings per share (EPS TTM) ALEC (Alector)|Earnings per share for the trailing year ANNX|Omeros Corp. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Neurogene Inc|AC Immune Corp (ACIU) - Earnings per share for the last twelve months|Voyager Corp - Earnings per share for the trailing year|NMRA (Neumora Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) scilexholding.com|Earnings per share for the last twelve months Tevogen Bio (TVGN)|ACOG: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) CGTX (Cognition Therapeutics)|Inhibikase Pharma (IKT) - Net earnings per one share for the last twelve months|SAVA: Net earnings per share for the last 12 months|ASRT - Net earnings per share (EPS TTM)|COYA (coyatherapeutics.com) - Net earnings per share for the last 12 months|VTGN: Earnings per share for the last four quarters|OVID (Ovid Therapeutics Inc) - Net earnings per share (EPS TTM)|Acumen Pharmaceuticals, Inc (ABOS) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) CRVO|Net earnings per share for the last 12 months alteritytherapeutics.com ATHE|Earnings per share for the last twelve months Clene CLNN|Net earnings per share for the last four quarters PepGen Inc (PEPG)|Jupiter Neurosciences Inc - Net earnings per share (EPS TTM)|Relmada Corp (RLMD) - Net earnings per share for the last 12 months|ANVS: Net earnings per share (EPS TTM)|Grace Therapeutics - Earnings per share for the trailing year|Earnings per share for the last twelve months Firefly Neuroscience|KLTO: Earnings per share for the trailing year|Earnings per share for the last twelve months NeuroSense Therapeutics (NRSN)|RVPH - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months MetaVia MTVA|NRXS: Earnings per share for the last 12 months|Helius Medical Technologies Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Passage Bio, Inc.|NEUP (bionomics.com.au) - Net earnings per share for the last 12 months|Minerva (NERV) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Athira Pharma, Inc.|ADXN: Earnings per share for the trailing year|Earnings per share for the last twelve months Alzamend Neuro, Inc. (ALZN)|CYCN - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) PTIX (Protagenic Therapeutics, Inc.)|KTTA - Net earnings per share for the last 12 months|Cortigent Medical - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ATXI (avenuetx.com)|BrainStorm Cell Therapeutics (BCLI) - Earnings per share for the last twelve months|Cara Therapeutics Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Eliem Therapeutics, Inc.|Net earnings per one share for the last twelve months Intra-Cellular ITCI|Earnings per share for the last twelve months Longboard Pharmaceuticals (LBPH)|Net earnings per share for the last 12 months marinuspharma.com MRNS|Earnings per share for the last twelve months NKGen Biotech NKGN|NeuroBo Pharmaceuticals Inc (NRBO) - Net earnings per one share for the last twelve months|Sage Therapeutics, Inc - Net earnings per share (EPS TTM)|Synaptogenix, Inc (SNPX) - Net earnings per share for the last 12 months|TRVN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Vigil Neuroscience, Inc. (VIGL)|Earnings per share for the last twelve months Anew Medical|Earnings per share for the last twelve months CERE
